JP2014522236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014522236A5 JP2014522236A5 JP2014509817A JP2014509817A JP2014522236A5 JP 2014522236 A5 JP2014522236 A5 JP 2014522236A5 JP 2014509817 A JP2014509817 A JP 2014509817A JP 2014509817 A JP2014509817 A JP 2014509817A JP 2014522236 A5 JP2014522236 A5 JP 2014522236A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 70
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 241000282465 Canis Species 0.000 claims 15
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 12
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 12
- 229940053128 nerve growth factor Drugs 0.000 claims 12
- 238000006467 substitution reaction Methods 0.000 claims 10
- 241000282472 Canis lupus familiaris Species 0.000 claims 7
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 108091008604 NGF receptors Proteins 0.000 claims 3
- 101150111783 NTRK1 gene Proteins 0.000 claims 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 102220645367 Immunoglobulin J chain_V24A_mutation Human genes 0.000 claims 2
- 102220500287 Lysosomal alpha-glucosidase_D10G_mutation Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 102220585298 Serine/threonine-protein kinase STK11_E16G_mutation Human genes 0.000 claims 2
- 102220590621 Spindlin-1_T19R_mutation Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 102200152029 rs2245803 Human genes 0.000 claims 2
- 102220126689 rs886044337 Human genes 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102220509400 E3 ubiquitin-protein ligase HUWE1_T27V_mutation Human genes 0.000 claims 1
- 102220486979 Sodium-dependent phosphate transport protein 1_S76N_mutation Human genes 0.000 claims 1
- 102220519680 Transcription factor E2F1_E14D_mutation Human genes 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 125000003147 glycosyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102220281547 rs1555514410 Human genes 0.000 claims 1
- 102220039281 rs199473357 Human genes 0.000 claims 1
- 102220046945 rs267608437 Human genes 0.000 claims 1
- 102200021640 rs2722372 Human genes 0.000 claims 1
- 102220012488 rs397516129 Human genes 0.000 claims 1
- 102200027728 rs62642916 Human genes 0.000 claims 1
- 102220322685 rs777811020 Human genes 0.000 claims 1
- 102220092750 rs876657859 Human genes 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483481P | 2011-05-06 | 2011-05-06 | |
| US61/483,481 | 2011-05-06 | ||
| GBGB1114858.2A GB201114858D0 (en) | 2011-08-29 | 2011-08-29 | Anti-nerve growth factor antibodies and methods of using the same |
| GB1114858.2 | 2011-08-29 | ||
| US201161531439P | 2011-09-06 | 2011-09-06 | |
| US61/531,439 | 2011-09-06 | ||
| PCT/GB2012/051002 WO2012153121A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017031939A Division JP2017101064A (ja) | 2011-05-06 | 2017-02-23 | 抗神経成長因子抗体並びに前記抗体の製造及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014522236A JP2014522236A (ja) | 2014-09-04 |
| JP2014522236A5 true JP2014522236A5 (enExample) | 2015-05-07 |
Family
ID=44838842
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509820A Active JP5990701B2 (ja) | 2011-05-06 | 2012-05-08 | 治療用イヌ免疫グロブリンおよびそれを用いる方法 |
| JP2014509817A Pending JP2014522236A (ja) | 2011-05-06 | 2012-05-08 | 抗神経成長因子抗体並びに前記抗体の製造及び使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509820A Active JP5990701B2 (ja) | 2011-05-06 | 2012-05-08 | 治療用イヌ免疫グロブリンおよびそれを用いる方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10040849B2 (enExample) |
| EP (3) | EP2705054B1 (enExample) |
| JP (2) | JP5990701B2 (enExample) |
| KR (4) | KR101637502B1 (enExample) |
| CN (4) | CN103732620B (enExample) |
| AU (2) | AU2012252151B2 (enExample) |
| BR (2) | BR112013028654A2 (enExample) |
| CA (3) | CA2835092C (enExample) |
| DK (1) | DK2705057T3 (enExample) |
| ES (2) | ES2601400T3 (enExample) |
| GB (1) | GB201114858D0 (enExample) |
| HU (1) | HUE030654T2 (enExample) |
| MY (2) | MY161724A (enExample) |
| PL (1) | PL2705057T3 (enExample) |
| PT (1) | PT2705057T (enExample) |
| RU (3) | RU2626527C1 (enExample) |
| SG (5) | SG10201500954WA (enExample) |
| WO (2) | WO2012153126A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| CN101014364B (zh) | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| WO2015091914A2 (en) * | 2013-12-20 | 2015-06-25 | Intervet International B.V. | Caninized murine antibodies to human pd-1 |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| WO2016050721A1 (en) | 2014-09-30 | 2016-04-07 | Intervet International B.V. | Pd-l1 antibodies binding canine pd-l1 |
| RU2736732C2 (ru) | 2015-04-02 | 2020-11-19 | Интервет Интернэшнл Б.В. | Антитела к альфа-рецептору собачьего интерлейкина-4 |
| US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| AR104721A1 (es) * | 2015-05-22 | 2017-08-09 | Astellas Pharma Inc | Fragmento fab anti-ngf humano |
| HK1257490A1 (zh) * | 2015-08-31 | 2019-10-25 | 宾夕法尼亚大学 | 用於治疗犬癌症的嵌合aav-抗vegf |
| EP4541807A3 (en) | 2015-12-18 | 2025-09-24 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| US11008387B2 (en) | 2016-01-06 | 2021-05-18 | Order-Made Medical Research Inc. | Antibody inhibiting binding of VEGF to NRP1 |
| JP6910963B2 (ja) * | 2016-01-06 | 2021-07-28 | 株式会社オーダーメードメディカルリサーチ | 高親和性抗ｖｅｇｆ抗体 |
| EP3416984B1 (en) * | 2016-02-18 | 2021-03-31 | Elanco US Inc. | Chimeric canine anti-cd20 antibody |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| KR20200130696A (ko) * | 2018-03-12 | 2020-11-19 | 조에티스 서비시즈 엘엘씨 | 항-ngf 항체 및 이의 방법 |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| MX2021007680A (es) * | 2018-12-27 | 2021-10-13 | Kindred Biosciences Inc | Variantes de igg fc para uso veterinario. |
| US12435143B2 (en) | 2019-07-15 | 2025-10-07 | Intervet Inc. | Caninized antibodies against canine CTLA-4 |
| CA3167437A1 (en) | 2020-02-19 | 2021-08-26 | Verena BRAND | Modified fc regions |
| US20230110287A1 (en) * | 2020-03-03 | 2023-04-13 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| CN116568708A (zh) * | 2020-10-07 | 2023-08-08 | 硕腾服务有限责任公司 | 抗ngf抗体和其使用方法 |
| US20230391862A1 (en) * | 2020-10-22 | 2023-12-07 | Scout Bio, Inc. | Method of suppressing immune response to vector-delivered therapeutic protein |
| BR112023022707A2 (pt) | 2021-05-12 | 2024-01-16 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molécula de ligação ao antígeno a qual se liga especificamente a rankl e ngf, e seu uso médico |
| JP2024535706A (ja) | 2021-08-31 | 2024-10-02 | スカウト バイオ， インコーポレイテッド | 抗原結合分子及びその使用 |
| JP2026502203A (ja) | 2022-12-27 | 2026-01-21 | インベテックス インコーポレイテッド | 新生仔ｆｃ受容体（ｆｃｒｎ）との改変された結合を伴うポリペプチド及び使用方法 |
| KR20250151402A (ko) | 2023-01-20 | 2025-10-21 | 인베티엑스 인코포레이티드 | 반려 동물에서 사용하기 위한 이중특이적 결합제 |
| FR3148027A1 (fr) * | 2023-04-24 | 2024-10-25 | Peptinov | Composition vaccinale anti-ngf |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| JP2837240B2 (ja) * | 1990-06-07 | 1998-12-14 | 財団法人化学及血清療法研究所 | イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体 |
| AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| GB9202796D0 (en) | 1992-02-11 | 1992-03-25 | Wellcome Found | Antiviral antibody |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| US6703360B2 (en) | 2000-04-07 | 2004-03-09 | Heska Corporation | Compositions and methods related to canine IgG and canine IL-13 receptors |
| DK1332209T3 (da) | 2000-09-08 | 2010-03-29 | Univ Zuerich | Samlinger af repeatproteiner indeholdende repeatmoduler |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US20030190705A1 (en) | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
| AU2002359851A1 (en) * | 2001-12-21 | 2003-07-30 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| ATE491444T1 (de) * | 2003-02-19 | 2011-01-15 | Rinat Neuroscience Corp | Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung |
| JP4263951B2 (ja) * | 2003-06-20 | 2009-05-13 | 財団法人日本生物科学研究所 | イヌ化抗体の作成方法および使用 |
| JP2005104936A (ja) * | 2003-10-01 | 2005-04-21 | Nippon Zenyaku Kogyo Kk | イヌｔａｒｃ抗体 |
| JP2005143436A (ja) * | 2003-11-18 | 2005-06-09 | Nippon Zenyaku Kogyo Kk | イヌｍｄｃ |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| ES2338344T3 (es) * | 2004-04-07 | 2010-05-06 | Rinat Neuroscience Corporation | Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal. |
| JP2008510466A (ja) * | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
| US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| CA2694055A1 (en) * | 2007-08-01 | 2009-02-05 | Glaxo Group Limited | Novel antibodies |
| US8722587B2 (en) * | 2008-04-09 | 2014-05-13 | The Trustees Of The University Of Pennsylvania | Single chain fragment variable antibody libraries and uses thereof |
| WO2010027488A2 (en) * | 2008-09-04 | 2010-03-11 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| WO2010110838A2 (en) | 2009-03-25 | 2010-09-30 | Vet Therapeutics Inc. | Antibody constant domain regions and uses thereof |
| US20120093814A1 (en) | 2009-03-30 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Fusion Proteins Comprising Canine FC Portions |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| WO2012024650A2 (en) | 2010-08-19 | 2012-02-23 | Abbott Laboratories | Anti-ngf antibodies and their use |
| EP2688908B1 (en) | 2011-03-23 | 2017-06-21 | Option Pharmaceuticals, LLC | Targeted cytokine for treatment of musculoskeletal diseases |
| US9328164B2 (en) | 2011-05-06 | 2016-05-03 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
-
2011
- 2011-08-29 GB GBGB1114858.2A patent/GB201114858D0/en not_active Ceased
-
2012
- 2012-05-08 RU RU2016102995A patent/RU2626527C1/ru active
- 2012-05-08 CN CN201280033531.XA patent/CN103732620B/zh active Active
- 2012-05-08 AU AU2012252151A patent/AU2012252151B2/en active Active
- 2012-05-08 SG SG10201500954WA patent/SG10201500954WA/en unknown
- 2012-05-08 ES ES12723733.7T patent/ES2601400T3/es active Active
- 2012-05-08 ES ES12723730T patent/ES2704036T3/es active Active
- 2012-05-08 CN CN201280033616.8A patent/CN103732622A/zh active Pending
- 2012-05-08 EP EP12723730.3A patent/EP2705054B1/en active Active
- 2012-05-08 KR KR1020137032546A patent/KR101637502B1/ko active Active
- 2012-05-08 EP EP18205440.3A patent/EP3502137A1/en active Pending
- 2012-05-08 KR KR1020167017621A patent/KR20160079939A/ko not_active Ceased
- 2012-05-08 AU AU2012252156A patent/AU2012252156B2/en active Active
- 2012-05-08 KR KR1020177016065A patent/KR20170070271A/ko not_active Ceased
- 2012-05-08 BR BR112013028654A patent/BR112013028654A2/pt not_active Application Discontinuation
- 2012-05-08 US US14/115,784 patent/US10040849B2/en active Active
- 2012-05-08 BR BR112013028523A patent/BR112013028523A8/pt not_active Application Discontinuation
- 2012-05-08 SG SG10201500960TA patent/SG10201500960TA/en unknown
- 2012-05-08 HU HUE12723733A patent/HUE030654T2/en unknown
- 2012-05-08 CN CN201610287357.1A patent/CN105999261A/zh active Pending
- 2012-05-08 JP JP2014509820A patent/JP5990701B2/ja active Active
- 2012-05-08 CN CN201610180304.XA patent/CN105833268A/zh active Pending
- 2012-05-08 DK DK12723733.7T patent/DK2705057T3/en active
- 2012-05-08 SG SG2013081922A patent/SG194796A1/en unknown
- 2012-05-08 WO PCT/GB2012/051008 patent/WO2012153126A1/en not_active Ceased
- 2012-05-08 SG SG2013081906A patent/SG194794A1/en unknown
- 2012-05-08 RU RU2013154304A patent/RU2644235C2/ru active
- 2012-05-08 JP JP2014509817A patent/JP2014522236A/ja active Pending
- 2012-05-08 EP EP12723733.7A patent/EP2705057B8/en active Active
- 2012-05-08 WO PCT/GB2012/051002 patent/WO2012153121A1/en not_active Ceased
- 2012-05-08 PT PT127237337T patent/PT2705057T/pt unknown
- 2012-05-08 CA CA2835092A patent/CA2835092C/en active Active
- 2012-05-08 PL PL12723733T patent/PL2705057T3/pl unknown
- 2012-05-08 KR KR1020137032543A patent/KR101783398B1/ko active Active
- 2012-05-08 RU RU2013154302A patent/RU2627191C2/ru active
- 2012-05-08 MY MYPI2013702082A patent/MY161724A/en unknown
- 2012-05-08 CA CA2906505A patent/CA2906505C/en active Active
- 2012-05-08 CA CA2834992A patent/CA2834992C/en active Active
- 2012-05-08 MY MYPI2013702079A patent/MY161295A/en unknown
- 2012-05-08 SG SG10201607259TA patent/SG10201607259TA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014522236A5 (enExample) | ||
| JP2019147801A5 (enExample) | ||
| SI2780368T1 (en) | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A | |
| JP2014519317A5 (enExample) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| RU2020129387A (ru) | Антитела к pd-1 собак | |
| PH12014500089A1 (en) | Antibodies that bind to ox40 and their uses | |
| JP2014534237A5 (enExample) | ||
| PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| JP2019536806A5 (enExample) | ||
| RU2021114500A (ru) | НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ | |
| RU2012142231A (ru) | Антитела против csf-1r человека и их применение | |
| JP2016536322A5 (enExample) | ||
| WO2016207304A8 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2013531993A5 (enExample) | ||
| JP2017501130A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| BR112014002613A2 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método | |
| JP2015532644A5 (enExample) | ||
| JP2014516026A5 (enExample) | ||
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| JP2013535190A5 (enExample) | ||
| PE20161221A1 (es) | Anticuerpos de il-21 | |
| JP2017502023A5 (enExample) |